Natalizumab induced blood eosinophilia: A retrospective pharmacovigilance cohort study and review of the literature.

Diem, L.; Hoepner, R.; Bagnoud, M.; Salmen, A.; Chan, A.; Friedli, C. (2021). Natalizumab induced blood eosinophilia: A retrospective pharmacovigilance cohort study and review of the literature. Journal of neuroimmunology, 353, p. 577505. Elsevier 10.1016/j.jneuroim.2021.577505

[img]
Preview
Text
Diem__2021__Natalizumab_induced_blood_eosinophilia.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (1MB) | Preview

OBJECTIVE

To describe frequency of natalizumab related eosinophilia and clinical symptoms of eosinophilic disease in our monocentric cohort.

METHODS

Comparison of clinical characteristics of 115 natalizumab treated and 116 untreated RRMS patients and review of literature.

RESULTS

38% of natalizumab treated patients had eosinophilia, which occurred significantly more frequently compared to untreated MS patients (3%, p-value<0.001). In symptomatic patients, mean eosinophil counts were significantly higher than in asymptomatic patients and symptoms developed within one year.

DISCUSSION

Eosinophilia is a side effect of natalizumab and mostly asymptomatic. However, few patients develop within one year after start of natalizumab an eosinophilic disease as severe side effect.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology

UniBE Contributor:

Diem, Lara; Hoepner, Robert; Bagnoud, Maud Marie; Salmen, Anke; Chan, Andrew Hao-Kuang and Friedli, Christoph Daniel

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0165-5728

Publisher:

Elsevier

Language:

English

Submitter:

Chantal Kottler

Date Deposited:

30 Jun 2021 12:22

Last Modified:

04 Jul 2021 03:08

Publisher DOI:

10.1016/j.jneuroim.2021.577505

PubMed ID:

33548621

Uncontrolled Keywords:

Immunotherapy Multiple sclerosis Natalizumab Pulmonary eosinophilia Side effects

BORIS DOI:

10.48350/157139

URI:

https://boris.unibe.ch/id/eprint/157139

Actions (login required)

Edit item Edit item
Provide Feedback